298 related articles for article (PubMed ID: 28654150)
21. Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa.
Boer J; Jemec GB
Clin Exp Dermatol; 2010 Jan; 35(1):36-40. PubMed ID: 19549239
[TBL] [Abstract][Full Text] [Related]
22. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents.
Matusiak Ł; Szczęch J; Bieniek A; Nowicka-Suszko D; Szepietowski JC
J Am Acad Dermatol; 2017 Apr; 76(4):670-675. PubMed ID: 28041632
[TBL] [Abstract][Full Text] [Related]
23. Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report.
van der Zee HH; Prens EP
Dermatology; 2013; 226(2):97-100. PubMed ID: 23713053
[TBL] [Abstract][Full Text] [Related]
24. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study.
Frew JW; Navrazhina K; Grand D; Sullivan-Whalen M; Gilleaudeau P; Garcet S; Ungar J; Krueger JG
J Am Acad Dermatol; 2020 Nov; 83(5):1341-1348. PubMed ID: 32416208
[TBL] [Abstract][Full Text] [Related]
25. Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study.
van der Zee HH; Laman JD; de Ruiter L; Dik WA; Prens EP
Br J Dermatol; 2012 Feb; 166(2):298-305. PubMed ID: 22013960
[TBL] [Abstract][Full Text] [Related]
26. Target molecules for future hidradenitis suppurativa treatment.
Zouboulis CC; Frew JW; Giamarellos-Bourboulis EJ; Jemec GBE; Del Marmol V; Marzano AV; Nikolakis G; Sayed CJ; Tzellos T; Wolk K; Prens EP
Exp Dermatol; 2021 Jun; 30 Suppl 1():8-17. PubMed ID: 34085329
[TBL] [Abstract][Full Text] [Related]
27. Clindamycin as unique antibiotic choice in Hidradenitis Suppurativa.
Rosi E; Pescitelli L; Ricceri F; Di Cesare A; Novelli A; Pimpinelli N; Prignano F
Dermatol Ther; 2019 Mar; 32(2):e12792. PubMed ID: 30515931
[TBL] [Abstract][Full Text] [Related]
28. AISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa.
Chiricozzi A; Faleri S; Franceschini C; Caro RD; Chimenti S; Bianchi L
Wounds; 2015 Oct; 27(10):258-64. PubMed ID: 26479209
[TBL] [Abstract][Full Text] [Related]
29. Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure.
Arenbergerova M; Arenberger P; Marques E; Gkalpakiotis S
Int J Dermatol; 2020 Jun; 59(6):733-735. PubMed ID: 32012238
[No Abstract] [Full Text] [Related]
30. A Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa: A Critical Evaluation of Mechanistic and Clinical Relevance.
Frew JW; Marzano AV; Wolk K; Join-Lambert O; Alavi A; Lowes MA; Piguet V
J Invest Dermatol; 2021 Feb; 141(2):316-324.e2. PubMed ID: 32919760
[TBL] [Abstract][Full Text] [Related]
31. Biology of Interleukin-17 and Novel Therapies for Hidradenitis Suppurativa.
Sabat R; Gudjonsson JE; Brembilla NC; van Straalen KR; Wolk K
J Interferon Cytokine Res; 2023 Dec; 43(12):544-556. PubMed ID: 37824200
[TBL] [Abstract][Full Text] [Related]
32. Use of biological treatments in patients with hidradenitis suppurativa.
Martin-Ezquerra G; Masferrer E; Masferrer-Niubò M; Ferran M; Sánchez-Regaña M; Collgros H; Bordas X; Notario J; Alsina M; Gil I; Izquierdo N; Aparicio G; Mollet J; Garcia-Patos V; Pujol RM
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):56-60. PubMed ID: 24629001
[TBL] [Abstract][Full Text] [Related]
33. Treatment Outcomes of IL-17 Inhibitors in Hidradenitis Suppurativa: A Systematic Review.
Kashetsky N; Mufti A; Alabdulrazzaq S; Lytvyn Y; Sachdeva M; Rahat A; Yeung J
J Cutan Med Surg; 2022; 26(1):79-86. PubMed ID: 34365863
[TBL] [Abstract][Full Text] [Related]
34. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
Kimball AB; Kerdel F; Adams D; Mrowietz U; Gelfand JM; Gniadecki R; Prens EP; Schlessinger J; Zouboulis CC; van der Zee HH; Rosenfeld M; Mulani P; Gu Y; Paulson S; Okun M; Jemec GB
Ann Intern Med; 2012 Dec; 157(12):846-55. PubMed ID: 23247938
[TBL] [Abstract][Full Text] [Related]
35. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.
Miller I; Lynggaard CD; Lophaven S; Zachariae C; Dufour DN; Jemec GB
Br J Dermatol; 2011 Aug; 165(2):391-8. PubMed ID: 21457202
[TBL] [Abstract][Full Text] [Related]
36. Pain management in patients with hidradenitis suppurativa.
Horváth B; Janse IC; Sibbald GR
J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S47-51. PubMed ID: 26470616
[TBL] [Abstract][Full Text] [Related]
37. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease.
Berman HS; Villa NM; Shi VY; Hsiao JL
J Dermatolog Treat; 2021 Mar; 32(2):261-263. PubMed ID: 31389737
[TBL] [Abstract][Full Text] [Related]
38. Secukinumab may be remedy for systemic amyloidosis findings secondary to hidradenitis suppurativa.
Tas-Aygar G; Gonul M; Ozcan I; Ayli MD; Ertoy-Baydar D
Dermatol Ther; 2020 Nov; 33(6):e14205. PubMed ID: 32829493
[TBL] [Abstract][Full Text] [Related]
39. Combination of oral zinc gluconate and topical triclosan: An anti-inflammatory treatment modality for initial hidradenitis suppurativa.
Hessam S; Sand M; Meier NM; Gambichler T; Scholl L; Bechara FG
J Dermatol Sci; 2016 Nov; 84(2):197-202. PubMed ID: 27554338
[TBL] [Abstract][Full Text] [Related]
40. Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa.
Jiménez-Gallo D; de la Varga-Martínez R; Ossorio-García L; Collantes-Rodríguez C; Rodríguez C; Linares-Barrios M
Cytokine; 2018 Mar; 103():20-24. PubMed ID: 29289722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
